Kuvatris Therapeutics Renames, Cancels Shares Amid Restructuring

PaxMedica, Inc. has renamed to Kuvatris Therapeutics, Inc. and canceled all shares held by the Depositary Trust Company. This move suggests a major restructuring effort, which could have significant implications for its shareholders and market operations. Despite its poor valuation and lack of guidance, Spark's AI Analyst gives PXMD a "Sell" signal with a negative P/E ratio.